Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

Suggested remit: To appraise the clinical and cost effectiveness of cabozantinib within its marketing authorisation for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that have progressed after systemic treatment.

Status:

In progress

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Process:

STA Standard

ID number:

6474

Provisional Schedule

Committee meeting:

10 September 2025

Expected publication:

19 November 2025

Project Team

Project lead

Kate Moore

Email enquiries

If you have any queries please email [email protected]

External Assessment Group:

BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors

Ipsen (cabozantinib)

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

Bowel Cancer UK

 

Neuroendocrine Cancer UK

Professional groups

Association of Cancer Physicians

 

Cancer Research UK

 

Royal College of Physicians

 

Society for Endocrinology

 

UKI NETS

Associated public health groups

None

Comparator companies

Accord Healthcare (5-fluorouracil, temozolomide) (confidentiality agreement not signed, not participating)

 

Amarox (capecitabine) (confidentiality agreement not signed, not participating)

 

Baxter (doxorubicin) (confidentiality agreement not signed, not participating)

 

Dr Reddy’s Laboratories (capecitabine, everolimus, sunitinib) (confidentiality agreement not signed, not participating)

 

Esteve Pharmaceuticals (streptozocin) (confidentiality agreement not signed, not participating)

 

Ethypharm UK (everolimus) (confidentiality agreement not signed, not participating)

 

Glenmark Pharmaceuticals (capecitabine) (confidentiality agreement not signed, not participating)

 

Hospira UK (carboplatin, cisplatin, 5-fluorouracil) (confidentiality agreement not signed, not participating)

 

medac GmBH (doxorubicin, 5-fluorouracil,) (confidentiality agreement not signed, not participating)

 

Merck Sharp & Dohme (temozolomide) (confidentiality agreement not signed, not participating)

 

MSN Laboratories (sunitinib) (confidentiality agreement not signed, not participating)

 

Mylan (sunitinib) (confidentiality agreement not signed, not participating)

 

Neon Healthcare (etoposide) (confidentiality agreement not signed, not participating)

 

Novartis (everolimus, lutetium (177Lu) oxodotreotide) (confidentiality agreement not signed, not participating)

 

Pfizer (doxorubicin, sunitinib) (confidentiality agreement not signed, not participating)

 

Piramal Critical Care (sunitinib) (confidentiality agreement not signed, not participating)

 

Sandoz (cisplatin, everolimus, sunitinib) (confidentiality agreement not signed, not participating)

 

Seacross (doxorubicin) (confidentiality agreement not signed, not participating)

 

Sun Pharma (temozolomide) (confidentiality agreement not signed, not participating)

 

Teva Pharma (sunitinib) (confidentiality agreement not signed, not participating)

 

Zentiva (sunitinib) (confidentiality agreement not signed, not participating)

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health, Social Services and Public Safety for Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

NHS Wales Joint Commissioning Committee

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

None

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual